Subscribe free

Cytoreductive Surgery & Peritoneum ·

Prophylactic CRS and HIPEC Elevate Outcomes in Appendiceal Cancer

Prophylactic cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) offers significantly improved survival for patients with perforated appendiceal adenocarcinoma.

  • Five-year overall survival with prophylactic CRS + HIPEC was 96.9% vs. 51.9% for conventional carcinologic resection.
  • Five-year disease-free survival was 75.2% with prophylactic treatment compared to 34.3% in the standard group.

This approach should be a standard discussion point for surgical teams handling perforated appendiceal tumors.

  • Postoperative morbidity rates were similar across all treatment groups, indicating safety in expanding surgical options.

Journal Article by Leiritz E, Fawaz J (…) Pocard M et 11 al. in Ann Surg Oncol

© 2025. Society of Surgical Oncology.

read the whole article in Ann Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →